Merck KGaA Submits IND Application in China for M9140, a Novel Anti-CEACAM5 Antibody-Drug Conjugate
May 17, 2024 13:33
CST Updated
13:33
Merck Group
Pharmaceutical R&D Developer
May 17,According to the CDE official website, Merck KGaA's Class 1 new drugM9140 for InjectionClinical trial application accepted. According to publicly available data, M9140 is an anti-CEACAM5 ADC。
M9140 is MerckDeveloped using proprietary technologyAn antibody-drug conjugate (ADC) targeting cancer cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
Merck Partial Pipeline
Summary
Based on the principle of CEA-targeted drug delivery, in recent yearsCEA, as one of the commonly used tumor markers in clinical practice, has entered the ADC track.。ChinaA total of 90 pipelines targeting CEACAM5 have been developed globally, currently inClinical Stage: 10 Pipeline Projects.
